Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
NSE - Free Realtime Quote INR

Laurus Labs Limited (LAURUSLABS.NS)

Compare
434.60 +0.05 (+0.01%)
As of 1:09 PM GMT+5:30. Market Open.
Loading Chart for LAURUSLABS.NS
DELL

Laurus Labs Limited Overview Drug Manufacturers - Specialty & Generic / Healthcare

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

www.lauruslabs.com

6,007

Full Time Employees

March 31

Fiscal Year Ends

Related News

View More

Performance Overview: LAURUSLABS.NS

Trailing total returns as of 7/25/2024, which may include dividends or other distributions. Benchmark is

S&P BSE SENSEX
.

YTD Return

LAURUSLABS.NS
1.12%
S&P BSE SENSEX
10.77%

1-Year Return

LAURUSLABS.NS
24.91%
S&P BSE SENSEX
20.54%

3-Year Return

LAURUSLABS.NS
32.16%
S&P BSE SENSEX
51.06%

5-Year Return

LAURUSLABS.NS
564.50%
S&P BSE SENSEX
111.44%

Compare To: LAURUSLABS.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LAURUSLABS.NS

View More

Valuation Measures

Annual
As of 7/24/2024
  • Market Cap

    235.02B

  • Enterprise Value

    259.40B

  • Trailing P/E

    146.31

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.69

  • Price/Book (mrq)

    5.70

  • Enterprise Value/Revenue

    5.19

  • Enterprise Value/EBITDA

    32.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.18%

  • Return on Assets (ttm)

    3.08%

  • Return on Equity (ttm)

    3.97%

  • Revenue (ttm)

    50.41B

  • Net Income Avi to Common (ttm)

    1.61B

  • Diluted EPS (ttm)

    2.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.42B

  • Total Debt/Equity (mrq)

    62.63%

  • Levered Free Cash Flow (ttm)

    -2.44B

Research Analysis: LAURUSLABS.NS

View More

Earnings Per Share

Consensus EPS
 

Analyst Price Targets

515.00
559.67 Average
434.60 Current
602.00 High
 

Company Insights: LAURUSLABS.NS

People Also Watch